X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with PLETHICO PHARMA - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs PLETHICO PHARMA - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA PLETHICO PHARMA AUROBINDO PHARMA/
PLETHICO PHARMA
 
P/E (TTM) x 17.8 -1.1 - View Chart
P/BV x 5.8 0.0 34,555.5% View Chart
Dividend Yield % 0.4 0.0 -  

Financials

 AUROBINDO PHARMA   PLETHICO PHARMA
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-16
PLETHICO PHARMA
Mar-14
AUROBINDO PHARMA/
PLETHICO PHARMA
5-Yr Chart
Click to enlarge
High Rs1,541395 390.1%   
Low Rs58231 1,859.4%   
Sales per share (Unadj.) Rs237.5604.4 39.3%  
Earnings per share (Unadj.) Rs33.932.5 104.3%  
Cash flow per share (Unadj.) Rs40.651.3 79.1%  
Dividends per share (Unadj.) Rs2.500-  
Dividend yield (eoy) %0.20-  
Book value per share (Unadj.) Rs120.6473.6 25.5%  
Shares outstanding (eoy) m585.1734.08 1,717.0%   
Bonus/Rights/Conversions PREF--  
Price / Sales ratio x4.50.4 1,267.6%   
Avg P/E ratio x31.36.6 477.6%  
P/CF ratio (eoy) x26.24.2 629.9%  
Price / Book Value ratio x8.80.5 1,955.7%  
Dividend payout %7.40-   
Avg Mkt Cap Rs m621,0417,262 8,551.4%   
No. of employees `00013.3NA-   
Total wages/salary Rs m15,5081,596 971.7%   
Avg. sales/employee Rs Th10,457.6NM-  
Avg. wages/employee Rs Th1,167.1NM-  
Avg. net profit/employee Rs Th1,491.6NM-  
INCOME DATA
Net Sales Rs m138,96120,598 674.6%  
Other income Rs m1,663386 430.4%   
Total revenues Rs m140,62420,984 670.1%   
Gross profit Rs m32,0562,818 1,137.7%  
Depreciation Rs m3,926642 611.3%   
Interest Rs m2,5681,593 161.2%   
Profit before tax Rs m27,225969 2,811.0%   
Minority Interest Rs m390-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,444-138 -5,379.2%   
Profit after tax Rs m19,8201,107 1,790.6%  
Gross profit margin %23.113.7 168.6%  
Effective tax rate %27.3-14.3 -191.4%   
Net profit margin %14.35.4 265.4%  
BALANCE SHEET DATA
Current assets Rs m100,01518,877 529.8%   
Current liabilities Rs m74,75911,896 628.4%   
Net working cap to sales %18.233.9 53.6%  
Current ratio x1.31.6 84.3%  
Inventory Days Days10736 298.8%  
Debtors Days Days110198 55.4%  
Net fixed assets Rs m52,3509,861 530.9%   
Share capital Rs m585341 171.8%   
"Free" reserves Rs m67,70712,331 549.1%   
Net worth Rs m70,56716,139 437.3%   
Long term debt Rs m8,4724,706 180.0%   
Total assets Rs m156,99433,146 473.6%  
Interest coverage x11.61.6 721.6%   
Debt to equity ratio x0.10.3 41.2%  
Sales to assets ratio x0.90.6 142.4%   
Return on assets %14.38.1 175.1%  
Return on equity %28.16.9 409.5%  
Return on capital %37.712.3 307.1%  
Exports to sales %51.021.4 238.8%   
Imports to sales %18.815.2 123.8%   
Exports (fob) Rs m70,9274,402 1,611.1%   
Imports (cif) Rs m26,1933,136 835.2%   
Fx inflow Rs m71,0154,402 1,613.1%   
Fx outflow Rs m28,7993,184 904.5%   
Net fx Rs m42,2161,219 3,464.6%   
CASH FLOW
From Operations Rs m17,5962,437 721.9%  
From Investments Rs m-13,801-6,265 220.3%  
From Financial Activity Rs m-1982,490 -8.0%  
Net Cashflow Rs m3,597-1,337 -269.0%  

Share Holding

Indian Promoters % 54.1 82.7 65.4%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 8.0 4.3 184.9%  
FIIs % 27.7 5.5 503.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 7.5 136.0%  
Shareholders   69,601 10,665 652.6%  
Pledged promoter(s) holding % 8.6 85.7 10.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   CADILA HEALTHCARE  TTK HEALTHCARE  ORCHID PHARMA LTD  DISHMAN PHARMA  J.B.CHEMICALS  

Compare AUROBINDO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Finishes on a Strong Note; Bank & Realty Stocks Rally(Closing)

Indian share markets surged further in the afternoon session and finished in the green for the second straight session on heavy buying in realty stocks, metal stocks and bank stocks.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

This Small Cap Can Drive Chinese Players Out of India (and Make a Fortune in the Process)(The 5 Minute Wrapup)

Aug 17, 2017

A small-cap Indian company with high-return potential and blue-chip-like stability is set to supplant the Chinese players in this niche segment.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

It's the Best Time to Buy IT Stocks(Daily Profit Hunter)

Aug 16, 2017

The IT Sector could be in an uptrend till February 2019. Are you prepared to ride the trend?

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 23, 2017 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - LUPIN LTD COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS